L&c Bio Co., Ltd.KRX: 290650

H1 2026 revenue reached KRW 69.1B, with improved net loss and major global expansion

· Issued by L&c Bio Co., Ltd.

Revenue for H1 2026 was KRW 69.1B, with a net loss of KRW -25.4B, showing improvement year-over-year. The company completed a major Chinese subsidiary acquisition, expanded its R&D pipeline, and announced a significant rights offering to fund growth and debt repayment.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Earlier from L&c Bio

All L&c Bio news releases